The Effect of Fish Oil in Major Depressive Disorder

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Kuan-Pin, National Science Council, Taiwan
ClinicalTrials.gov Identifier:
NCT01371383
First received: June 7, 2011
Last updated: May 11, 2012
Last verified: May 2012
  Purpose

The first part is a double-blind placebo-controlled trial to identify the effects of omega-3 polyunsaturated fatty acids (PUFAs) monotherapy in depression. The second part is a double-blind trial to identify the effects of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on different symptom clusters in patients with depression.


Condition Intervention Phase
Major Depressive Disorder
Dietary Supplement: Omega-3 fatty acids
Dietary Supplement: placebo
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Effect of Fish Oil in Major Depressive Disorder: a Double-blind Placebo-controlled Monotherapy Trail to Demonstrate the Therapeutic Effects of Depression

Resource links provided by NLM:


Further study details as provided by National Science Council, Taiwan:

Primary Outcome Measures:
  • Changes in Hamilton Depression Rating Scale (HDRS) [ Time Frame: Weeks 0 and 8 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Changes in Beck Depression Inventory (BDI) [ Time Frame: Weeks 0 and 8 ] [ Designated as safety issue: No ]
  • Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: Weeks 0 and 8 ] [ Designated as safety issue: Yes ]

Enrollment: 120
Study Start Date: January 2005
Study Completion Date: April 2012
Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: omega-3 fatty acids Dietary Supplement: Omega-3 fatty acids
1.6~2.8 gram/day (5 capsules)
Other Name: DHA/EPA
Placebo Comparator: Placebo Dietary Supplement: placebo
5 gram/day (5 capsules)
Other Name: control

Detailed Description:

With the dissatisfaction of monoamine-based pharmacotherapy and the high comorbidity of physical illness in depression, the serotonin hypothesis seems to fail in approaching the etiology of depression. Based upon the evidence from epidemiological data, case-control studies of PUFAs levels in human tissues, and antidepressant effect in clinical trials, phospholipid PUFAs is enlightening a promising path to discover the unsolved of depression.

The PUFAs are classified into n-3 (or omega-3) and n-6 (or omega-6) groups. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), the major bioactive components of n-3 PUFAs, are not synthesized in humans and can only be obtained directly from the diet, particularly by consuming fish. The deficit of n-3 PUFAs has been reported to be associated with neurological, cardiovascular, cerebrovascular, autoimmune, and metabolic diseases. Recent studies revealed that the deficit of n-3 PUFAs is also associated with depression. More specifically, societies that consume a small amount of omega-3 PUFAs appear to have a higher prevalence of major depressive disorder. In addition, depressive patients had showed a lower level of omega-3 PUFAs; and the antidepressant effect of PUFAs had been reported in a number of clinical trials. Theoretically, DHA deficit is associated with dysfunctions of neuronal membrane stability and transmission of serotonin, norepinephrine and dopamine, which might connect to etiology of depression. On the other hand, EPA is important in balancing the immune function by reducing membrane arachidonic acid (AA, an n-6 PUFA) and prostaglandin E2 (PGE2) synthesis. Interestingly, animals fed with high AA diet or treated with PGE2 present sickness behaviors of anorexia, low activity, change in sleep pattern and attention, which are similar to somatic symptoms of depression in human.

There are little data at this stage to reveal whether the oral administration of omega-3 fatty acids monotherapy would lead to an effective mood stabilization in major depressive disorder. In addition, the active component of antidepressant effect in n-3 PUFAs is still unknown. In this project, the first part is a double-blind placebo-controlled trial to identify the effects of omega-3 PUFAs monotherapy in depression. The second part is a double-blind trial to identify the effects of EPA and DHA on different symptom clusters in patients with depression.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. DSM-IV criteria for major depressive disorder.
  2. Age being age 18-65.
  3. Capacity and willingness to give written informed consent.

Exclusion Criteria:

  1. Any major medical illnesses.
  2. A recent or past history of any Axis-I diagnoses besides major depressive disorder, including psychotic disorders; cognitively impaired mental disorders; impulse control disorders; substance use disorder or substance abuse (last 6 months prior to the studies); primary anxiety disorders, including post-traumatic stress disorder and panic disorder; and bipolar disorders; or Axis-II diagnoses, i.e. borderline and antisocial personality disorder.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01371383

Locations
Taiwan
China Medical University Hospital
Taichung, Taiwan, 404
Sponsors and Collaborators
National Science Council, Taiwan
Investigators
Principal Investigator: Kuan-Pin Su, MD PhD China Medical University Hospital
  More Information

No publications provided

Responsible Party: Kuan-Pin, China Medical University Hospital, National Science Council, Taiwan
ClinicalTrials.gov Identifier: NCT01371383     History of Changes
Other Study ID Numbers: DOH94F044
Study First Received: June 7, 2011
Last Updated: May 11, 2012
Health Authority: Taiwan: Department of Health

Additional relevant MeSH terms:
Depressive Disorder
Depression
Depressive Disorder, Major
Disease
Mood Disorders
Mental Disorders
Behavioral Symptoms
Pathologic Processes

ClinicalTrials.gov processed this record on October 19, 2014